Why AnaptysBio Fell by as Much as 10% Today

By The Motley Fool8 days ago

AD

On Tuesday, AnaptysBio (NASDAQ: ANAB) traded down nearly 10% at one point, before recovering to end the day 2.5% higher. There wasn't any direct news driving such sentiments; rather, it seems other factors were at play.

AnaptysBio is a clinical-stage biotech that concentrates on immunology therapies -- currently a hot area of development in the healthcare world.

At the moment, its leading pipeline drug is imsidolimab, which is currently being developed to treat moderate to severe cases of a rare autoimmune disease called generalized palmoplantar pustulosis.

Continue reading

Continue read on fool.com